A drug designed to block the advance of type 1 diabetes in its earliest stages is strikingly effective in the phase 2 clinical trial, according to researchers at the University of California, San Francisco. Click here to read the full story.
The UCSF Pediatric Diabetes Program led by Steve Gitelman, MD, has made progress in altering the course of type 1 diabetes. Through various screening tests, we are now able to identify relatives at risk for developing type 1 diabetes. For those at risk, there are currently three prevention trials that seek to prevent or delay the onset of disease.
A new Diabetes Center study highlights the potential importance of the vast majority of human DNA that lies outside of genes within the cell. Faculty member Michael McManus, PhD, graduate student Ian Vaughn, and postdoctoral fellow Matthew Hangauer, PhD, identified thousands of previously unknown, unique RNA sequences by looking at which regions of the genome are converted into RNA. RNA is a molecule that increasingly is being found to play myriad important roles within cells.
Shingo Kajimura, PhD, was named a 2013 Pew Scholar in the Biomedical Sciences which provides flexible funding to early-career scientists who are pursuing the most promising, but untried, avenues for scientific breakthroughs.
Over the next 25 years, the number of Americans with diabetes is expected to double, and the economic costs of diabetes will almost triple. The need for a cure is urgent. In the Diabetes Center at UCSF, we believe that innovative, collaborative research is the answer. Through communication and a spirit of common purpose, our team of internationally renowned scientists and physicians is solidly united in the search for improved treatments and a cure.
We are proud to announce that Greg Ku, MD, PhD will join both our research and clinical care teams as Assistant Professor in the Diabetes Center and as a member of the Division of Endocrinology and Metabolism in the Department of Medicine.
Thanks to generous private philanthropy, our award-winning educational website, Diabetes Education Online, was recently translated into both Chinese and Spanish, making quality online diabetes education available to millions of patients managing diabetes worldwide.
Mark Anderson, MD, PhD, is the 2013 recipient of the UCSF Byers Award for Basic Science, granted to recognize and support the outstanding research of a mid-career faculty member within all of UCSF. Dr. Anderson, the Robert B. Friend and Michelle M. Friend Endowed Chair in Diabetes Research, works at the intersection of diabetes, genetics, and stem cells and is making great advances in understanding autoimmune diseases such as type 1 diabetes.
As part of the Diabetes Center’s mission to improve the quality of care for patients, the Madison Clinic for Pediatric Diabetes has implemented a program to assist older youth in their transition to adulthood.
UCSF Diabetes Center researchers Matthias Hebrok, PhD, and Mark Anderson, MD, PhD, have created in their labs the first functioning human thymus tissue derived from embryonic stem cells – a huge step forward in producing new cell therapies to treat numerous diseases including type 1 diabetes.
Join TEAM UCSF in participating in the American Diabetes Association (ADA) Tour de Cure scheduled for Sunday, May 5th in the Napa Valley. This cycling event raises money to fund diabetes research. If you haven't already sponsored your favorite UCSF Diabetes Center team member, please find that person at our team site and donate to their fundraising effort!
Center Director Matthias Hebrok, PhD, and his lab colleagues have optimized existing culture conditions to increase the number of pancreas progenitor cells and insulin-producing cells from human stem cells. Their current studies indicate that they are getting closer to generating functional beta cells for transplantation purposes.
As another year concludes, I continue to feel enormous pride for all that we have accomplished. It is only because of you – our supporters and donors – that we have been successful in creating one of the most respected diabetes research and clinical centers in the world. As we continue on our path to create new, more effective treatments for type 1 and type 2 diabetes, I remain grateful for our ongoing partnership.